Full Papers
Abatacept and tofacitinib in refractory sarcoidosis: drug survival, safety, and treatment response
H.C.B. Leffers1, B. Baslund2, J. Lindhardsen3, S.B. Krintel4, N. Graudal5
- Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. henrik.christian.bidstrup.leffers@regionh.dk
- Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
- Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
- Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
- Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
CER17449
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 39360380 [PubMed]
Received: 08/01/2024
Accepted : 02/05/2024
In Press: 03/10/2024
Abstract
OBJECTIVES:
To describe drug survival, safety and treatment response in sarcoidosis patients treated with abatacept or tofacitinib in routine care.
METHODS:
We identified 41 sarcoidosis patients treated with abatacept and 12 patients treated with tofacitinib. Of the patients treated with tofacitinib 83% had previously been treated with abatacept. Drug survival and reasons for discontinuation of treatment was investigated. Treatment response was evaluated at least once within the first 6 months of treatment by at least one trained clinician and classified as responder or non-responder. No direct comparison of drugs was made.
RESULTS:
Median (range) disease duration was 3.5 (1–27) and 3 (1–16) years for abatacept and tofacitinib. The patients had previously received a median of 1 DMARD and 1 biological DMARD in both groups. Nearly all patients had been treated with at least one TNFi (95%/92 %). After 6 months, 90% (95%CI 85–90%) of the 41 patients in the abatacept group and 89% (79–99%) of the 12 patients in the tofacitinib group-maintained treatment. At 12 months, it was 80% (73–87%) and 74% (58–90%). No serious adverse events were recorded. For abatacept and tofacitinib 71% and 67% of patients were characterised as responders. In both treatment groups, there was a significant reduction in prednisolone dosage and levels of soluble IL2-receptor at all time points.
CONCLUSIONS:
Sarcoidosis patients treated with abatacept and tofacitinib had long drug survival, achieved high response rates. Both drugs represent good and safe therapeutic options in sarcoidosis patient’s refractory to previous TNFi therapy.